Apyx Medical Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APYX research report →
Range $6 – $7
Price Chart
About the company
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures.
- CEO
- Charles D. Goodwin
- IPO
- 2019
- Employees
- 205
- HQ
- Clearwater, FL, US
Get TickerSpark's AI analysis on APYX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $101.10M
- P/E
- -12.14
- PEG
- -0.18
- P/S
- 1.70
- P/B
- 11.12
- EV/EBITDA
- -72.78
- Div Yield
- 0.00%
- Gross Margin
- 34.47%
- Op Margin
- -5.50%
- Net Margin
- -14.16%
- ROE
- -70.78%
- ROIC
- -6.39%
Latest fiscal year · YoY change
- Revenue
- $52.84M+9.9%
- Gross Profit
- $19.03M-35.2%
- Op Income
- $-6,446,000
- Net Income
- $-11,211,000+52.2%
- EPS
- $-0.27+59.1%
- OCF Growth
- +55.7%
- FCF Growth
- +51.4%
- 52W High
- $5.08
- 52W Low
- $2.25
- 50D MA
- $2.68
- 200D MA
- $3.51
- Beta
- 1.31
- RSI (14)
- 37
- Avg Volume
- 146.07K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Apyx delivered 9% revenue growth in Q3 on AYON and international Renuvion strength, while tightening full-year expense guidance and reaching positive trailing-12-month EBITDA.· November 5, 2026
- Total revenue rose 9% year over year to $14 million, led by AYON in the U.S. and Renuvion outside the U.S.
- Surgical Aesthetics revenue grew 17% to $13 million; OEM revenue fell 41.5% to $1.1 million as the company deprioritized that business.
- Gross margin was 64.2%, essentially flat with last year’s 64.4%, while adjusted EBITDA turned positive at $0.4 million.
- Management said AYON Power Lipo is a key adoption catalyst and that the product can be activated via software update and handpiece/cannula purchase.
- Full-year 2026 revenue guidance was reaffirmed at $59 million to $60 million, with operating expense guidance tightened to $41 million to $42.5 million.
Third-quarter 2026 revenue was $14 million, up 9% from $12.9 million a year ago. Surgical Aesthetics revenue increased 17% to $13 million, while OEM revenue declined 41.5% to $1.1 million. Gross profit was $9 million versus $8.3 million last year, and gross margin was 64.2% compared with 64.4% in the prior-year period. Net loss attributable to shareholders was $1.8 million, or $0.04 per share, versus $2 million, or $0.05 per share, last year; adjusted EBITDA was $0.4 million versus an adjusted EBITDA loss of $0.1 million. Cash and cash equivalents were $25.8 million, and operating cash use was $1.6 million for the quarter. For full-year 2026, the company reaffirmed revenue guidance of $59 million to $60 million, expects Surgical Aesthetics revenue of $54 million to $55 million and OEM revenue of about $5 million, and now expects gross margin of 63% to 64% with operating expenses of $41 million to $42.5 million.
Charlie Goodwin emphasized that AYON is the main growth driver and said Power Lipo was a pivotal catalyst for adoption because it broadens the system’s appeal to the estimated 70% of plastic surgeons who use power liposuction. He framed AYON and Renuvion as complementary technologies that address fat removal and skin contraction, and he highlighted new clinical evidence supporting Renuvion’s skin-quality benefits. His tone was upbeat and expansionary, stressing that the company is just getting started in the U.S. and is working toward international registrations in key markets.
Matt Hill focused on the operating model and margins, noting that gross profit rose 9% to $9 million while gross margin held at 64.2%, with the slight decline tied mainly to geographic and product mix. He said operating expenses were $9.6 million in the quarter, net cash used in operations was $1.6 million, and cash on hand was $25.8 million, with average cash burn around $2 million per quarter this year. He also tightened 2026 operating expense guidance to $41 million to $42.5 million from the prior expectation of less than $45 million, while reaffirming revenue guidance and expecting gross margin of 63% to 64%.
Analysts focused on what is driving better profitability, the rollout pace for AYON and Power Lipo, and when international approvals might come. Management said the business is now EBITDA positive on a trailing-12-month basis, that the company has already made the investments needed for the full commercial launch, and that AYON demand should remain a multiyear tailwind. On geography, management said no specific approval timelines can be given, but it is prioritizing Europe, the Middle East, Brazil, Colombia, and Mexico; it also said U.S. comparisons will remain difficult because AYON shipped against a partial-year launch in the prior year.
The quarter showed that AYON and Renuvion can drive growth while improving profitability, with adjusted EBITDA turning positive and management saying the company is already EBITDA positive on a trailing-12-month basis. Management also pointed to positive surgeon feedback on Power Lipo, early adoption of the full AYON workflow, and a large international opportunity as registrations progress.
OEM revenue is declining sharply, and management expects that business to fall for the year as the company shifts focus to Surgical Aesthetics. Growth comparisons in the U.S. will also get tougher because last year’s AYON launch created an uneven baseline, and management gave no timeline for key international approvals. Although cash is adequate for now, the company still used $1.6 million of operating cash in the quarter and is relying on continued execution to sustain profitability.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 86.4%
- Shares Outstanding
- 42.12M
- Float Shares
- 36.41M
of shares held by institutions
71 13F filers
Buy/sell ratio 2.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Royce & Associates LP | 3.50M | ▲ 229.03K |
| Nantahala Capital Management, LLC | 3.34M | ▲ 73.11K |
| Archon Capital Management LLC | 2.64M | ▼ 146.21K |
| Vanguard Group Inc | 1.57M | ▲ 36.13K |
| Kanen Wealth Management LLC | 1.55M | ▲ 1.48M |
| Vanguard Capital Management LLC | 1.53M | 0 |
| Aigh Capital Management LLC | 1.13M | 0 |
| Blackrock, Inc. | 553.61K | ▼ 7.38K |
| Horizon Kinetics Asset Management LLC | 460.00K | ▼ 125.00K |
| Geode Capital Management, LLC | 402.78K | ▲ 2.18K |
| Taylor Frigon Capital Management LLC | 395.43K | ▼ 18.18K |
| Renaissance Technologies LLC | 383.39K | ▼ 170.88K |
Held by 31 ETFs
Biggest fund positions in APYX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | Waldman Lawrence | other | 12,000 |
| Jun 30, 26 | Waldman Lawrence | other | 5,024 |
| Jun 30, 26 | Waldman Lawrence | other | 12,000 |
| Jun 15, 26 | Roman Shawn David | other | 10,533 |
| Jun 15, 26 | Roman Shawn David | other | 15,000 |
| Jun 15, 26 | Roman Shawn David | other | 15,000 |
| Jun 11, 26 | Levine Wendy Lauren | other | 50,000 |
| Jun 11, 26 | Vizirgianakis Stavros G. | other | 450,000 |
| Jun 11, 26 | Goodwin Charles D. II | other | 213,948 |
| Jun 11, 26 | Roman Shawn David | other | 88,044 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our APYX coverage
Recent articles, reports, and earnings notes.
Want a deeper read on APYX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Apyx Medical Corporation (APYX) Presents at 2026 UBS Global Healthcare Conference Transcript
seekingalpha.com · Nov 9
Apyx Medical Corporation (APYX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
Apyx Medical (APYX) Reports Q3 Loss, Tops Revenue Estimates
zacks.com · Nov 5
Apyx Medical Q3 Earnings Call Highlights
marketbeat.com · Nov 5
Apyx Medical Corporation Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 5
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Apyx Medical Corporation (NASDAQ: APYX)
prnewswire.com · Oct 22
Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026
globenewswire.com · Oct 22
Apyx Medical Corporation to Participate in Upcoming Investor Conferences
globenewswire.com · Oct 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
